	US 12,440,604 B2
	Bone regeneration in compromised wounds
Juan M. Taboas, Pittsburgh, PA (US); Alejandro Jose Almarza, Pittsburgh, PA (US); and Jingming Chen, Chicago, IL (US)
Assigned to University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Appl. No. 17/055,046
Filed by University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
PCT Filed Jun. 13, 2019, PCT No. PCT/US2019/037081 § 371(c)(1), (2) Date Nov. 12, 2020, PCT Pub. No. WO2019/241577, PCT Pub. Date Dec. 19, 2019.
Claims priority of provisional application 62/684,401, filed on Jun. 13, 2018.
Prior Publication US 2021/0213170 A1, Jul. 15, 2021
Int. Cl. A61L 27/38 (2006.01); A61L 27/26 (2006.01); A61L 27/52 (2006.01); A61L 27/54 (2006.01); A61M 5/19 (2006.01)

CPC A61L 27/3847 (2013.01) [A61L 27/26 (2013.01); A61L 27/3834 (2013.01); A61L 27/52 (2013.01); A61L 27/54 (2013.01); A61M 5/19 (2013.01); A61L 2300/236 (2013.01); A61L 2300/252 (2013.01); A61L 2300/414 (2013.01); A61L 2300/426 (2013.01); A61L 2400/06 (2013.01); A61L 2430/02 (2013.01)]

11 Claims

1. A biomaterial comprising:

a hydrogel comprising the crosslinked polymers PEG, gelatin, and a glycosaminoglycan with sulfated moiety, wherein a ratio of the glycosaminoglycan with sulfated moiety to the PEG by mass is 1/1 or greater; and

chondrogenic, osteogenic, and immunomodulatory cytokines, wherein the cytokines comprise TGF-β1;

wherein the biomaterial is acellular, the biomaterial comprises about 1 mg/ml of the TGF-β1, and the biomaterial is capable of potentiating bone regeneration in a compromised wound while reducing inflammatory response in a large animal.